[{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"IMU-856","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Immunic","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sankyo \/ Immunic"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Nestle Health Science","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ Nestle Health Science"},{"orgOrder":0,"company":"Contract Sales Organization","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Triethanolamine Salicylate","moa":"COX-2","graph1":"Gastroenterology","graph2":"Approved","graph3":"Contract Sales Organization","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Contract Sales Organization \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Contract Sales Organization \/ Tetra Bio-Pharma"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"Galacto-oligosaccharide","moa":"Lactase enzyme","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Metoclopramide","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Teva Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase?C","graph1":"Gastroenterology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Allergan Aesthetics \/ Teva Pharmaceuticals"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Large molecule","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ ASTRAZENECA","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ ASTRAZENECA"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Berlin Chemie \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"Berlin Chemie \/ Helsinn Group"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"RHB-106","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dibuprenorphine-ethyl-ether","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"PPAR-gamma","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Norgine \/ Faes Farma S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Faes Farma S.A."},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"PvP Biologics \/ Takeda","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biologics \/ Takeda"},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Dusquetide","moa":"p62 protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Not Applicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Reloxaliase","moa":"Oxalate","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Anaprazole sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Sihuan Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sihuan Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"Il-2 mutein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Approved","graph3":"Massachusetts General Hospital","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Massachusetts General Hospital \/ Royalty Pharma"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Iliad Research and Trading","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Iliad Research and Trading","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Iliad Research and Trading"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Linaprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Fourth Swedish National Pension Fund"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Bismuth Subsalicylate","moa":"COX","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"HDP","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Cellspan Esophageal Implant","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Not Applicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase II","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"8","companyTruncated":"InDex Pharmaceuticals \/ Vinnova"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":1.54,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":1.54,"dosageForm":"","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Genome \/ Gilead Sciences"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AG013","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Mouth Rinse","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"Il-12","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cara Care","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Hyoscine Butyl Bromide","moa":"M3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cara Care","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Cara Care \/ Sanofi ","highestDevelopmentStatusID":"12","companyTruncated":"Cara Care \/ Sanofi "},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ RDD Pharma"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Salix Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ABI-M201","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antolimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aerpio Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Aerpio Pharmaceuticals \/ Gossamer","highestDevelopmentStatusID":"6","companyTruncated":"Aerpio Pharmaceuticals \/ Gossamer"},{"orgOrder":0,"company":"Synlogic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Synthetic Biotic medicines","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Synlogic \/ AbbVie"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Xiling Lab \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antolimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ BofA Securities"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin Cell adhesion molecule-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Gastroenterology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ JSR"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BT051","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Thylakoid extract","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Devonian Health Group \/ Not Applicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ AbbVie"},{"orgOrder":0,"company":"Quest Products","sponsor":"Quest Products, LLC","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Docusate Potassium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Quest Products","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Quest Products \/ Quest Products, LLC","highestDevelopmentStatusID":"12","companyTruncated":"Quest Products \/ Quest Products, LLC"},{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Gastroenterology","graph2":"Approved","graph3":"Edge Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edge Pharma \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Edge Pharma \/ ANI Pharmaceuticals"},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"OPL-002","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oppilan Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oppilan Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oppilan Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dusquetide","moa":"p62 protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ UCB"},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plakous Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Therapeutics \/ National Institute of Health"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner International \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":63,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":63,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AbbVie"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Macrogol","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ColonaryConcepts \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Not Applicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"NM-002","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"T Cell surface glycoprotein CD3","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Life Sciences \/ ThinkEquity"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ RedHill Biopharma"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Health \/ Not Applicable"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"SB-121","moa":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Medicine \/ Galapagos"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"PR600","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IMU-856","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HK inno.N \/ Not Applicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"Beta-7 integrin Ligand binding","graph1":"Gastroenterology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"RTX-1688","moa":"15-Hydroxyprostaglandin dehydrogenase","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Approved","graph3":"Highmark","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Highmark \/ UCB"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ Oasis Capital"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sibofimloc","moa":"E coli fimH protein blocker","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"TPG Capital IP","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ellodi Pharmaceuticals \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ TPG Capital IP"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KB295","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fosaprepitant","moa":"NK1 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lovastatin Lactone","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naldemedine Tosylate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sandoz B2B \/ Shionogi","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Shionogi"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Greenteaspoon","sponsor":"PanTheryx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Prebiotics","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Greenteaspoon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Greenteaspoon \/ PanTheryx","highestDevelopmentStatusID":"12","companyTruncated":"Greenteaspoon \/ PanTheryx"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"ALV-304","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Alivio Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland BioLabs","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Noroxymorphone analogs","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland BioLabs"},{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Surveyor Capital"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"Beta-7 integrin Ligand binding","graph1":"Gastroenterology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BX002","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Not Applicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Plecanatide","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"IntelGenx \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Tetra Bio-Pharma"},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Maltosyl-isomaltooligosaccharide","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive \/ Virginia Catalyst"},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Not Applicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Ga